Abstract. in the last decade, micrornas (mirnas; small noncoding rna molecules) as post-transcriptional regulators have been a hotspot in research for their involvement in biological processes and tumour development. However, there have been few reviews focusing on a single mirna family. the dysregulation of mirnas appears to play a crucial role in cancer pathogenesis where they exert their effect as oncogenes or as tumour suppressors. this review summarises current studies on the dysregulation of the microrna-34 (mir-34) family in different types of cancers and its role in the p53 network. the structure of the mir-34 family members includes p53-binding sites reflecting their function as tumour suppressors downstream of the p53 pathway. mir-34 dysregulation occurs in cancers, including several epithelial cancers, melanomas, neuroblastomas, leukemias and sarcomas, in the presence or absence of the p53 mutation. for these cancers, functional restoration of mir-34 is a useful novel therapy. as evidenced from preclinical and clinical studies, the mir-34 family plays an important role in the treatment of mir-34-dysregulated cancers with mutant or wild-type p53. this review will have a potential impact in the clinical treatment of p53-mutant and/or mir-34-dysregulated cancers using a mir-34 restoration approach.
Introduction
micrornas (mirnas) are small regulatory noncoding rnas that repress gene expression at the post-transcriptional level in a sequence-specific manner. They play a crucial role in varying aspects of cell proliferation, differentiation and apoptosis (1) . However, the vast number of mirna genes, their varied expression patterns and the wealth of potential mirna targets suggest that mirnas are likely to be involved in an extended spectrum of human pathologies (2) . alterations in their expression have displayed correspondence with disease states in pathologic conditions such as alzheimer's disease. factors required for mirna processing and/or function have also been involved in fragile X mental retardation (3) and Digeorge syndrome (4) . mirna dysregulation is also associated with the initiation and development of cancer (5-7) as they are misexpressed in malignant tumours with respect to their normal tissue equivalents. table i summarises the mechanisms in which this occurs. calin et al demonstrated that greater than half of human mirnas map to fragile or cancer-associated genomic regions that are susceptible to deletions, amplifications or recombination (8) . Such locations suggest that various mirnas are involved in tumourigenesis (8) (9) (10) . mirnas cause either tumour suppression or tumour development. one class includes oncogenes, also known as oncomirs, whose expression is upregulated in tumours. they catalyse tumour development by negatively inhibiting tumoursuppressor genes. conversely, mirna expression may also be downregulated in cancerous cells. these types of mirnas are considered tumour-suppressor genes which prevent tumour development by negatively inhibiting oncogenes.
Since the first miRNA was described in 1993 (11) , many new mirnas have been discovered (12) (13) (14) , and currently a mirna registry (http://www.sanger.ac.uk/software/rfam/) contains sequence data on more than 10,500 mirnas. However, to date, a specific function has been assigned to just a few miRNAs. mirna-directed gene regulation is a rapidly emerging area of research and study, propelled by technological advancements in rna-based methods including cloning and size-fractionated rna strategies (12, 15, 16 (27, 28) and northern blot analysis of gene expression (29) . recently, next generation sequencing technologies are being readily employed to achieve a more precise portrayal of mirna expression profiles to enhance our understanding of the intricacy and methods of mirna regulation (30, 31) . Multiple reviews have summarised the mechanism of rna interference (32) (33) (34) (35) , the biogenesis of mirnas (36) (37) (38) and their role in gene regulation (39, 40) . this review focuses on an individual mirna family, mirna-34 (mir-34), regarding its intrinsic link with p53. this review aims to explore the research conducted on mir-34s for its role in the p53 network and relevant cancer treatment, specifically in regards to i) miR-34 structure and the p53-binding site, ii) mir-34 family in normal function, iii) p53 mutation and the role of mir-34 in cancer, and iv) the therapeutic potential of mir-34.
2. miR-34 structure and the p53-binding site the mir-34 family shares some general characteristics with mirnas. normally, mirnas are produced through a multistep progression involving two distinctive biogenetic pathways. During the maturation process, transcriptional and post-transcriptional levels are tightly monitored, ensuring accurate production. they are created from long primary transcripts that are developed in numerous steps to form cytoplasmic ~22-nucleotide mature mirnas (36, 41, 42) with the excision of a 30-kb intron (43). the mature mirna is then integrated into the mirna-induced silencing complex (miriSc), which directs it to target sequences. Most mirnas use their seed sequences on 5'-utrs (table ii) to recognize their target sites located in 3'-utrs by incomplete basepairing, resulting in mrna destabilization or translational repression of the target genes (44, 45) . the mir-34 family includes three processed mirnas (mir-34a, mir-34b, and mir-34c) that are encoded by two different genes (46, 47) (fig. 1 ). mir-34a is encoded by an individual transcript while mir-34b and mir-34c share a common primary transcript. the gene encoding mir-34a is located on human chromosome 1p36, while mir-34b and mir-34c are co-transcribed from one transcription unit on chromosome 11q23. animal studies have demonstrated that mir-34b/c is predominantly expressed in the lungs, and mir-34a is expressed in the brain, showing that they have tissue-specific functions (46) . An expression analysis following individual transfection of each mir-34 showed that the affected mrnas were almost indistinguishable. However, variations in the attractions for targets between the three mir-34 members occur. for instance, c-Myc is mainly regulated by mir-34b/c, evidenced by the enhanced complementarity between the mir-34b seed sequence and the seed-matching sequence in the c-Myc 3'-utr, when evaluated against mir-34a (48). the mirna-encoding sequences and short promoter proximal regions each house a consensus p53-binding site (47) anticipated to be within 30 kb of the precursor transcription units for all members of the mir-34 family. the proximity of the p53-binding site to both the mir-34a and mir-34b/c precursors has spurred the interest of many scientists.
miR-34 family in normal function
More than 60% of human protein-coding genes are conserved targets of mirna (49) (50) (51) . thus, they have diverse biological functions, including developmental timing, signal transduction and tissue differentiation (52) . the mir-34 family is an example of a single mirna family which performs numerous biological functions (table iii and table iV) . Mechanisms aberrant transcription of the precursors by the epigenetic silencing of mirna promoters through promoter methylation and histone acetylation; aberrant mirna processing due to altered expression of mirna biogenesis machinery; germline mutation of precursor mirna molecules; rarely, point mutations in mature mirnas or in target sequences that interfer with normal target recruitment. 
a Sequence alignment of mature mir-34a, mir-34b and mir-34c molecules. the seed sequences at the 5'-utrs in bold print are used to combine with targeted mrnas for regulation purposes. Regulation of cell cycle progression, apoptosis or senescence. the p53 protein is a transcription factor which blocks cell proliferation and stimulates cell death. it lies at the nexus of molecular pathways that monitor cellular disruptions and abnormal mitogenic activation (53) . cellular senescence and apoptosis, Dna-damaging agents, oxidative stress, and activation of oncogenes can all cause double-stranded breaks which stimulate atM kinases and consequently phosphorylate p53 (46) (fig. 2) . p53 orchestrates such responses by directly activating mir-34a and subsequent key genes through binding two repeats of the Dna sequence 5'-PuPuPuc(a/t)(t/a) gPyPyPy-3' (54). the p53 gene encodes effector proteins that induce cellular processes: p21 (g1-arrest), 14-3-3σ (g2-arrest) and Puma (apoptosis) (55) . miR-34a is the most significantly induced mirna which acts as a post-transcriptional target of p53 (46) . it controls the crucial tumour suppressive effects of p53 through a context-dependent induction of growth arrest, apoptosis or senescence (56-58) being partly responsible for the downregulation of anti-apoptotic proteins (55).
p53 mutation and the role of miR-34 in cancer
p53 is a tumour suppressor which needs to be disabled or disrupted for most types of cancers to differentiate and proliferate (59) . as such, mutations in the p53 pathway are figure 2. Molecular mechanisms in the p53-mir-34 network involved in regulating cell apoptosis. Briefly, wt-p53 activates miR-34 after DNA damage and/or cellular stress, which subsequently inhibits expression of anti-apoptotic genes and results in cell apoptosis and tumour suppression.
Crosses reflect the downregulation of anti-apoptotic proteins by miR-34. also shown is the regulation of Sirt1 by mir-34a as part of a positive feedback loop that leads to further activation of p53, once it has been activated. abbreviations of anti-apoptotic proteins: cDK4/6, cyclin-dependent kinase 4/6; e2f3, e2f transcription factor 3; Bcl-2, B-cell lymphoma 2; Sirt1, silent information regulator 1. Pancreatic cancer mir-34a Human pancreatic cell lines exhibit at least a 2-fold reduction in mir-34a restoration caused an inhibition of the expression of target genes, notch1/2 expression when compared to its expression in normal pancreatic cell lines and Bcl-2, leading to cSc self-renewal and/or cell fate determination. this (76) . MiaPaca2 cells, low in mir-34a expression, had enhanced levels of explains the 87% reduction in the tumour-initiating cell population (77) with tumour-initiating cells with elevated amounts of notch1/2 and Bcl-2 (77).
senescence and cell cycle arrest. additionally, restoration sensitised cancer cells to conventional therapeutic methods of chemotherapy and radiation (60) .
Breast cancer mir-34a reduced expression of mir-34a is found in triple-negative (i.e. negative upon the alteration of mir-34a expression levels in the mesenchymal line, expression of progesterone receptors, estrogen receptors and Her-2) and MDa-MB-231, it was found that increasing levels of mir-34a protected cells mesenchymal subsets (MDa-MB-231) compared to other breast cancer from radiation-induced cell death while reducing levels of mir-34a sensitised cell lines, such as Her-2 + tumours (uacc812). this can be explained by cells to radiation-induced cell death. this demonstrates that mir-34a is common mutations in p53 in the former subtypes of breast cancer (78, 79) .
required to protect cells from non-apoptotic cell death in mammalian MDa-MB-231 cells. these results suggest that mirna levels can also be employed to attenuate response to treatment as antagonizing mir-34a enhances the sensitivity of breast cancer cells towards radiation (79) .
Prostate cancer miR-34c miR-34c expression levels were significantly decreased in human p53-null miR-34c expression was found to be inversely associated with PC3 cell and p53-mutated Du145 cells as compared to lncaP cells expressing tumour aggressiveness, WHo grade, PSa levels and metastatic potential, wild-type p53 (80) . this is explained by the documented loss of heterosuggesting that mir-34c plays a role both in initiation and development of zygosity at 11q23 (the locus of mir-34b/c) in prostate cancer (81) .
the tumour (82) . restoration reduced levels of e2f3, a gene involved in cell cycle regulation at the g1/S checkpoint and was responsible for catalysing proliferation in prostate cell lines. this resulted in an impaired cellular proliferation rate and fewer cells in the S-phase. it also causes an increased apoptosis rate and a reduction in the anti-apoptotic protein Bcl-2 (82) and Sirt1 mrna (83) .
Colorectal miR-34a/b/c The majority (51-74%) of all colorectal cancers are p53-mutant which is miR-34a caused senescence-like growth arrest in human colon cancer (56) cancer responsible for mir-34a dysregulation in one-third of colorectal cancers. may restore p53 function (63) .
ovarian cancer mir-34b/c receptor protein tyrosine kinase Met is often overexpressed in epithelial mir-34 regulates cell propagation and invasion through targeting several ovarian cancers, responsible for the occurrence of metastases and motility (88) . genes such as Met, Myc and e2f3 (89) .
Melanoma mir-34a in p53-mutant cancers methylation of the mir-34a promoter occurs (60) reconstitution of mir-34a levels inhibited uveal melanoma cell proliferation resulting in reduced mir-34a expression.
and invasion through the downregulation of c-Met oncogene (90) .
international journal of oncology 38: 1189-1195, 2011 found in almost all forms of cancers (55) (fig. 3 ). p53 mutations have been linked with antagonistic tumour behaviour and poor clinical outcome (47) . p53 maps to 1p36 (the locus of mir-34a), a region of common loss in various cancer forms (47) . thus, comparatively low levels of mir-34s are observed in human tumours and cancer cell lines (60).
Therapeutic potential of miR-34
It is known that the expression levels of miR-34 are deficient in p53-mutant cancer cells. this explains the abundance of research surrounding 'mirna replacement therapy', which focuses on the concept that the re-introduction of mirnas suppressed in p53-mutant cancer cells reactivates cellular pathways that initiates a therapeutic response (61) (fig. 4) . this involves introducing synthetic mir-34 or mir-34 mimetics into pathological tissues in an effort to reinstate normal proliferation, apoptosis, and other cellular functions (62) . Specifically, the restoration of miR-34 was discovered to reduce the amount of tumour-initiating cells, or cancer stem cells (cScs) (63) . cScs are tumour cells persisting after chemotherapy that, in almost all cancers, prompt the regrowth of the tumour. characteristically, these cells are resistant to conventional therapies. as such, cancer treatment should be targeted against both resting cScs and proliferating cancer cells. a study found that ectopic expression of mir-34 induces cell cycle arrest in both human-primary and tumour-derived cell lines which is in line with the capacity of mir-34 to downregulate a set of genes promoting cell cycle progression (64). restoration dampens the levels of the e2f3 protein (58) . the mir-34a and tumours through downregulation of the c-Met oncogene (91) . in aggressive mir-34c precursor mimics stimulate striking growth inhibition in phenotypes, which express reduced levels of mir-34a compared to those neuroblastoma 2 cell lines with a 1p36 hemizygous deletion (93) .
with functional copies of 1p36, there is loss of 1p36 heterozygosity and MYCN gene amplification (92) . leukemia mir-34a a clinical study found that patients with a 17p13 deletion had an in human chronic myelocytic leukemia, the activation of extracellular signalunfavourable response to chemotherapy related to p53 inactivation. it found regulated protein kinase (erK) potently induced the expression of mir-34a that 37 of 99 patients with f-refractory chronic lymphocytic leukemia (cll) which subsequently repressed cell proliferation by inhibiting the expression had a tP53 mutation. f-refractory disease had a substantially lower baseline of mitogen-activated protein kinase kinase 1 (MeK1) (94) .
mir-34a expression than a control population of cll cases without refractory disease, tP53 loss, or mutation (65) .
Sarcoma mir-34a in p53-mutant cancers there was minimal deletions and epigenetic inactivation. 
Conclusion
this review demonstrates that p53, a potent tumour suppressor, modulates levels of mirnas, specifically mir-34s. the expression of mir-34s is robustly induced by Dna damage and oncogenic stress in a p53-dependent approach. When overexpressed, mir-34 causes apoptosis or cellular senescence, whereas reduction of mir-34 function attenuates p53-mediated cell death. These findings, in association with the concept that mir-34 is downregulated in several forms of human cancer, show that mirnas affect tumourigenesis by acting within the boundaries of established tumour-suppressor pathways. as such, they hold an important function in the treatment of p53-mutant or wild-type p53 cancers with dysregulated mir-34s using a mir-34 restoration approach. the restoration of functional mir-34 stimulates chemosensitisation and apoptosis, suggesting that mir-34 may restore p53 function. this inhibits tumour development as a result of the direct control of downstream anti-apoptotic proteins. thus, the restoration of the tumour suppressor mir-34 may provide a novel molecular therapy for p53-mutant cancers. this review will have a clinical impact on the treatment of p53-mutant and/or mir-34-dysregulated cancers using a mir-34 restoration approach. clinical studies using mir-34a (65) are underway and may provide further information to clarify the safety and efficacy of this molecule.
